Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin

Abstract Induction chemotherapy treatment for nasopharyngeal carcinoma (NPC) is controversial. The aim of this study was to evaluate the treatment outcomes and toxicities between two induction chemotherapy regimens, with both followed by concurrent chemoradiotherapy. The first strategy used docetaxe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhen Zeng, Ruo-Nan Yan, Li Tu, Yu-Yi Wang, Pei-Ran Chen, Feng Luo, Lei Liu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Concurrent Chemoradiotherapy (CCRT) Induction Chemotherapy Regimen Nasopharyngeal Carcinoma (NPC) Distant Metastasis-free Survival (DMFS) Adverse Toxicity Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c1503b99488349798598cb7d0c61b02c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c1503b99488349798598cb7d0c61b02c
record_format	dspace
spelling	oai:doaj.org-article:c1503b99488349798598cb7d0c61b02c2021-12-02T15:08:50ZAssessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin10.1038/s41598-018-33614-52045-2322https://doaj.org/article/c1503b99488349798598cb7d0c61b02c2018-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-33614-5https://doaj.org/toc/2045-2322Abstract Induction chemotherapy treatment for nasopharyngeal carcinoma (NPC) is controversial. The aim of this study was to evaluate the treatment outcomes and toxicities between two induction chemotherapy regimens, with both followed by concurrent chemoradiotherapy. The first strategy used docetaxel, cisplatin and fluorouracil for induction chemotherapy (TPF), and the second utilised gemcitabine and cisplatin (GP). A retrospective analysis was performed on eligible NPC patients attending our hospital between May 2009 and Dec 2014. A total of 113 patients were enrolled with 58 patients receiving TPF and 55 receiving GP induction chemotherapy. Ninety-four patients (83.2%) were alive after 36-months follow-up. The median overall survival (OS) and progression-free survival (PFS) time were 48.3 and 39.7 months, respectively. The 3-year OS for the TPF regimen was 87.9% and 87.4% with GP chemotherapy (P = 0.928). The 3-year PFS of the TPF treatment was 84.5%, while it was 83.5% for the GP group (P = 0.551). Univariate analysis showed that lymph node metastasis was a significant PFS prognostic factor, while N3 stage was an independent predictor of PFS and distant failure-free survival (DMFS) in multivariate analysis. There were no significant differences in adverse toxicities or treatment efficacy between the chemotherapy regimens in the treatment of locoregionally advanced NPC.Zhen ZengRuo-Nan YanLi TuYu-Yi WangPei-Ran ChenFeng LuoLei LiuNature PortfolioarticleConcurrent Chemoradiotherapy (CCRT)Induction Chemotherapy RegimenNasopharyngeal Carcinoma (NPC)Distant Metastasis-free Survival (DMFS)Adverse ToxicityMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Concurrent Chemoradiotherapy (CCRT) Induction Chemotherapy Regimen Nasopharyngeal Carcinoma (NPC) Distant Metastasis-free Survival (DMFS) Adverse Toxicity Medicine R Science Q
spellingShingle	Concurrent Chemoradiotherapy (CCRT) Induction Chemotherapy Regimen Nasopharyngeal Carcinoma (NPC) Distant Metastasis-free Survival (DMFS) Adverse Toxicity Medicine R Science Q Zhen Zeng Ruo-Nan Yan Li Tu Yu-Yi Wang Pei-Ran Chen Feng Luo Lei Liu Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
description	Abstract Induction chemotherapy treatment for nasopharyngeal carcinoma (NPC) is controversial. The aim of this study was to evaluate the treatment outcomes and toxicities between two induction chemotherapy regimens, with both followed by concurrent chemoradiotherapy. The first strategy used docetaxel, cisplatin and fluorouracil for induction chemotherapy (TPF), and the second utilised gemcitabine and cisplatin (GP). A retrospective analysis was performed on eligible NPC patients attending our hospital between May 2009 and Dec 2014. A total of 113 patients were enrolled with 58 patients receiving TPF and 55 receiving GP induction chemotherapy. Ninety-four patients (83.2%) were alive after 36-months follow-up. The median overall survival (OS) and progression-free survival (PFS) time were 48.3 and 39.7 months, respectively. The 3-year OS for the TPF regimen was 87.9% and 87.4% with GP chemotherapy (P = 0.928). The 3-year PFS of the TPF treatment was 84.5%, while it was 83.5% for the GP group (P = 0.551). Univariate analysis showed that lymph node metastasis was a significant PFS prognostic factor, while N3 stage was an independent predictor of PFS and distant failure-free survival (DMFS) in multivariate analysis. There were no significant differences in adverse toxicities or treatment efficacy between the chemotherapy regimens in the treatment of locoregionally advanced NPC.
format	article
author	Zhen Zeng Ruo-Nan Yan Li Tu Yu-Yi Wang Pei-Ran Chen Feng Luo Lei Liu
author_facet	Zhen Zeng Ruo-Nan Yan Li Tu Yu-Yi Wang Pei-Ran Chen Feng Luo Lei Liu
author_sort	Zhen Zeng
title	Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
title_short	Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
title_full	Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
title_fullStr	Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
title_full_unstemmed	Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
title_sort	assessment of concurrent chemoradiotherapy plus induction chemotherapy in advanced nasopharyngeal carcinoma: cisplatin, fluorouracil, and docetaxel versus gemcitabine and cisplatin
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/c1503b99488349798598cb7d0c61b02c
work_keys_str_mv	AT zhenzeng assessmentofconcurrentchemoradiotherapyplusinductionchemotherapyinadvancednasopharyngealcarcinomacisplatinfluorouracilanddocetaxelversusgemcitabineandcisplatin AT ruonanyan assessmentofconcurrentchemoradiotherapyplusinductionchemotherapyinadvancednasopharyngealcarcinomacisplatinfluorouracilanddocetaxelversusgemcitabineandcisplatin AT litu assessmentofconcurrentchemoradiotherapyplusinductionchemotherapyinadvancednasopharyngealcarcinomacisplatinfluorouracilanddocetaxelversusgemcitabineandcisplatin AT yuyiwang assessmentofconcurrentchemoradiotherapyplusinductionchemotherapyinadvancednasopharyngealcarcinomacisplatinfluorouracilanddocetaxelversusgemcitabineandcisplatin AT peiranchen assessmentofconcurrentchemoradiotherapyplusinductionchemotherapyinadvancednasopharyngealcarcinomacisplatinfluorouracilanddocetaxelversusgemcitabineandcisplatin AT fengluo assessmentofconcurrentchemoradiotherapyplusinductionchemotherapyinadvancednasopharyngealcarcinomacisplatinfluorouracilanddocetaxelversusgemcitabineandcisplatin AT leiliu assessmentofconcurrentchemoradiotherapyplusinductionchemotherapyinadvancednasopharyngealcarcinomacisplatinfluorouracilanddocetaxelversusgemcitabineandcisplatin
_version_	1718388025099026432

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin

Ejemplares similares